Author

Nina Fischer

University of AugsburgPrimary ORCID profile (0000-0002-0142-226X · 1 paper)Unclaimed ORCID profile · follow to get notified of new preprints

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Same name, identified by ORCID

Nina FischeriD1 paper · University of Zurich

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1

Frequent Co-Authors

Andrea StutziD· 1 shared Boris KubuschokiD· 1 shared Catherine BotteroniD· 1 shared Celine Baron· 1 shared Christian WernoiD· 1 shared Christoph A. KleiniD· 1 shared Dagmar Halbritter· 1 shared Dennis Christoph HarreriD· 1 shared

Activity by Year

2026-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Andrea StutzORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Ex vivo drug testing in metastatic biopsies reveals patient-specific vulnerabilities to cancer targeting and immune activating drugs

Lukas Wöhrl, Durdam Das, Kathrin Weidele, Steffi Treitschke, Celine Baron, Dagmar Halbritter, Catherine Botteron, Florian Lüke, Nataša Stojanović Gužvić, Melanie Werner‐Klein, Dennis Christoph Harrer, Tobias Pukrop, Julia Lanznaster, Thorsten Nitsch, Thomas Südhoff, , Christian Werno

This study introduces PEDRA, an ex vivo drug response assay that identifies patient-specific treatment options in metastatic biopsies, outperforming prior therapies and informing immune responses.

bioRxiv · Feb 9, 2026 · PreprintCancer Biology